Source comparison
BPC-157 for GERD Acid Reflux Research: Comparison
Primary Action Upregulates VEGF/FGF for mucosal angiogenesis; modulates NO pathways Irreversibly blocks H+/K+ ATPase pump in parietal cells Competitively blocks histamine H2 receptors on parietal cells BPC-157 targets tissue repair, not acid suppression. Compl
This comparison does not assign a generated winner or score.
- Primary Action
- Upregulates VEGF/FGF for mucosal angiogenesis; modulates NO pathways
- Irreversibly blocks H+/K+ ATPase pump in parietal cells
- Competitively blocks histamine H2 receptors on parietal cells
- BPC-157 targets tissue repair, not acid suppression. Complementary mechanism to existing therapies
- Acid Suppression
- Moderate reduction in hypersecretion (animal models)
- 90–95% reduction in gastric acid output
- 60–70% reduction in gastric acid output
- PPIs remain superior for acid control; BPC-157's value lies in mucosal healing
- Mucosal Healing Rate
- 60% lesion reduction in 24h (rodent ethanol model)
- Standard healing rate over 8 weeks in human trials
- Standard healing rate, slower than PPIs
- BPC-157 accelerates healing in preclinical models but lacks human validation
- Inflammatory Modulation
- Reduces TNF-α, IL-6, and oxidative stress markers
- No direct anti-inflammatory effect
- BPC-157's cytokine modulation could address reflux-driven inflammation PPIs don't touch
- Human Clinical Data
- None. No phase 1, 2, or 3 trials
- Extensive phase 3 data; FDA-approved for GERD
- BPC-157 is research-only; PPIs and H2 blockers have decades of safety data
- Regulatory Status
- Research peptide; not FDA-approved
- FDA-approved (omeprazole, lansoprazole, etc.)
- FDA-approved (ranitidine, famotidine)
- BPC-157 cannot be prescribed or marketed for GERD treatment